JPS5931454A - Aqueous solvent for testing clotting of red blood corpuscles - Google Patents

Aqueous solvent for testing clotting of red blood corpuscles

Info

Publication number
JPS5931454A
JPS5931454A JP14189382A JP14189382A JPS5931454A JP S5931454 A JPS5931454 A JP S5931454A JP 14189382 A JP14189382 A JP 14189382A JP 14189382 A JP14189382 A JP 14189382A JP S5931454 A JPS5931454 A JP S5931454A
Authority
JP
Japan
Prior art keywords
red blood
aqueous solvent
aqueous
blood cells
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP14189382A
Other languages
Japanese (ja)
Inventor
Yatsuhiro Kamimura
上村 八尋
Masakazu Tajima
田島 政和
Shozo Ishii
石井 昭三
Satoru Funakoshi
船越 哲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Priority to JP14189382A priority Critical patent/JPS5931454A/en
Publication of JPS5931454A publication Critical patent/JPS5931454A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555Red blood cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 技術分野 本弁明は、赤血球凝集試験用水性溶媒に関するものであ
る。
DETAILED DESCRIPTION OF THE INVENTION Technical Field The present invention relates to aqueous solvents for red blood cell agglutination tests.

抗原抗1体反応や、ある神の動植物菌体、又はウィルス
由来の凝梁物1.Bitと生体(什白γ1や赤血球との
憔集f☆応を3% i#I・することにより、そわらの
−万か又は+t+j者を定1目的に測定する方法は、赤
血球#集反応(PHA法)、逆受身赤血球凝集反応(R
PHA法)、細菌の凝集反応、又はラテックス凝集反応
などとして広く臨床(゛美食の分野で利用されている。
Antigen-antibody reaction, a certain animal, plant, bacterial cell, or virus-derived aggregate 1. The method of measuring the -10,000 or +t+j of Sowara for a fixed purpose is to measure the aggregation f☆reaction between Bit and living body (white γ1 and red blood cells by 3% i#I・). PHA method), reverse passive hemagglutination reaction (R
It is widely used clinically (in the field of gastronomy) as the PHA method), bacterial agglutination reaction, or latex agglutination reaction.

背踏技jlrr 例えばP II A法について説1す1す第1ば、精製
したllBs抗原をIj11#集試験川世体(用下担体
と略す)であるヒシジ赤血球に感作せしめてHBs抗原
感作ヒツジ赤血球を得、このものと曲成(1〜体とを解
合した時に水性溶媒中で凝集反応がみられるか否かによ
って検体中にJ(’Bs抗体が存在しているか杏かを判
定できる。
For example, regarding the P II A method, the first step is to sensitize purified llBs antigen to red blood cells, which are used as a carrier for the Ij11 test, to develop HBs antigen sensitivity. The presence of J('Bs antibodies in the sample was determined by whether or not an agglutination reaction was observed in an aqueous solvent when this was fused with a synthetic sheep red blood cell.) Can be judged.

また^ト集反応がみられた場合は、その検体を史に段階
的に希釈して凝集反応か観、察できなくなるまでの希釈
倍数を求めることにより、その(ii棒体中H’、13
 s抗体を定h1的に測定することができる。
In addition, if an aggregation reaction is observed, the sample is diluted stepwise and the dilution ratio until the agglutination reaction can no longer be observed or detected is determined.
s antibodies can be measured regularly.

またRP)(A法でlJ、精製したJJ、’B s抗体
を411体である赤血球に感作してllBs抗体(11
9作赤血球を製し、このものと検体とを胛1合した時に
水性階か4中で凝集反応がみられるか否かによって、検
体中にJ(I3s抗原が含まれているか否かを検知する
ことができる。
In addition, 411 erythrocytes were sensitized to 411 erythrocytes with RP) (lJ, purified JJ, 'Bs antibody using method A, and 11Bs antibody (11
When 9 red blood cells are prepared and the sample is combined with the sample, whether or not an agglutination reaction is observed in the aqueous solution is used to detect whether or not the sample contains J(I3s antigen). can do.

史にある神のウィルスと鳥類の赤血球とはウィルスの有
する凝集素の作用により赤血球を水性溶媒中で凝集する
。この水性溶媒中でのuF集反応の有無、強弱によって
ウィルスの八°(ル“を定量的に測定することかできる
。これら水性溶媒中での凝集反応を利用した分析方法は
、110便でかつ?111定M’? I’Mも旨いので
各神抗原や抗体の検査に広く利用さねていることは周知
のjjtJりである。
The divine virus in history and the red blood cells of birds agglutinate red blood cells in an aqueous solvent due to the action of the virus's agglutinin. Depending on the presence or absence and strength of the uF aggregation reaction in this aqueous solvent, it is possible to quantitatively measure the amount of virus. It is well known that I'M is also delicious and is widely used for testing various antigens and antibodies.

しかし、これら水性溶媒中での凝集試験に共Jt!’1
した欠点として、担体に対する抗体を含む(1力体にお
いては、非持異的な凝集反応かおこり判定を挾まるとい
う間W(1がある。従って、検体を測定する場合には、
これらの塀似反応物の彫物が出てこない程IWにまで予
め希釈した後に測定を行うか、もしくは適当な確認試験
法を用いて水性浴媒中での凝集反応の真偽を確かめる必
要がある。
However, in the aggregation test in these aqueous solvents, Jt! '1
However, the disadvantage of this method is that it contains antibodies against the carrier (in a single-force system, it is difficult to determine whether a non-specific agglutination reaction has occurred).Therefore, when measuring a sample,
It is necessary to perform the measurement after diluting the IW to such an extent that the engravings of these wall-like reactants do not come out, or to confirm the authenticity of the aggregation reaction in an aqueous bath medium using an appropriate confirmation test method. .

また、水性Mts中でのこれら非特異的凝集反応を少な
くする方法として、1tll+定に用いる水性溶媒の中
に少量の動物伽白やアクリノールを加える方法が既に知
られている。しかしこれらのlIθ−においてもある稈
IWの非持b¥; M集lシ応をμ/j山しつるが、尚
多くの非%異反応が残るので史に鋳第1だ11法の出現
か待Liノさねでいる。
In addition, as a method for reducing these non-specific aggregation reactions in aqueous Mts, a method is already known in which a small amount of animal pigment or acrinol is added to the aqueous solvent used for 1 tll+. However, even in these lIθ-, there is a lack of culm IW b¥; Although the M collection l reaction is μ/j mountain, there are still many non-percent reactions remaining, so the appearance of the first 11th method in history. I'm waiting for Li no Sane.

また、非特異反応を/l!l去する別の方法としてi’
i13体中の/lif似反応物貿をシ傅作していtcい
担体で予め0メタ着除去する方法もあるが、ル裟・(の
検体を1「tl時に短時間に処理するにはJ)まりにも
*tJAcである。
Also, for non-specific reactions /l! Another way to leave is i'
There is also a method of preparing /lif-like reactant trade in the i13 body and removing the 0 metal adhesion in advance with a tc carrier, but in order to process the sample in a short time at 1 tl, it is necessary to ) It's really *tJAc.

σ「つで1本発明の目的は非特異反応を消去し棚めて使
用(鰻屋の優れた〜果試騎月1水件溶妨を挫供せ/【と
するにある。
The purpose of the present invention is to eliminate non-specific reactions and store them for use.

発明のDり示 発明名等は永年この凝集反応における非特異反応を消去
するため測定方法の改良/rl)死へ偕は、動物由来の
胎盤組%l’″lル1分叉は助吟I組紳/j12.分を
測定系に存在させることにより?1Ilj定に’? I
Q−が顧者に改f1÷されること、さらに当nシ組廠1
r/分を特定、28度に存在させた場合に、特にtII
マしい到(果が得らtすることを−7出し、本発明を完
成した。
The name of the invention is the improvement of the measurement method to eliminate non-specific reactions in this agglutination reaction for many years. By making Class I/j12. minute exist in the measurement system, ?1Ilj is constant'?I
Q- is changed by the customer by f1 ÷, and furthermore, the assembly factory 1
r/min, especially when present at 28 degrees, tII
He completed the invention by getting -7.

即ち、本発明は動物由来の胎盤組織成分又は筋肉組織成
分を40.01〜0.4%(w/v)のtb度に含有す
ることを特徴とする赤血球凝集試験用水性浴(Ivに関
する。
That is, the present invention relates to an aqueous bath for red blood cell agglutination test (Iv) characterized by containing an animal-derived placental tissue component or muscle tissue component at a tb degree of 40.01 to 0.4% (w/v).

この水性溶媒を赤血球→シを集反応試験用試薬の調整に
用いることにより」二組測定感lWの改善を悴成するこ
とができる。
By using this aqueous solvent to prepare a reagent for a red blood cell collection reaction test, it is possible to improve the sensitivity of two sets of measurements.

水性溶媒としては、従来既知のあらゆる凝集試験用水性
俗媒が利用でき1例えば水、生理渡1t、A水、各神緩
辿S液(リン酸緩(資)液、ホウ酸緩衝液、クリシン緩
細浩)、アルブミン溶液、デキ、ストラン溶液、正常ヒ
ト及び動物血清溶Hシ、合成高分子物質の溶液、界面活
性剤含有水溶液、およびこれらの組み合せからなる溶液
が例示される。当該水性溶媒のpHは、約6.0〜8.
5が好ましく、かかるp Hへの調整は緩#I液でおこ
なわれることが好ましい。水性溶媒の塩濃度は、比較的
fル濃度であることが好ましく、より好ましくは、生理
的等幅な溶液である。
As the aqueous solvent, all known aqueous media for agglutination tests can be used. For example, water, 1 ton of menstrual fluid, A water, various slow S solutions (phosphate buffer, borate buffer, chrysin Examples include solutions consisting of aqueous solution containing a surfactant, an albumin solution, a dextrose solution, a stock solution, a solution of normal human and animal serum, a solution of a synthetic polymeric substance, an aqueous solution containing a surfactant, and a combination thereof. The pH of the aqueous solvent is approximately 6.0-8.
5 is preferable, and adjustment to such pH is preferably carried out with a mild #I solution. The salt concentration of the aqueous solvent is preferably a relatively high concentration, more preferably a physiologically equidistant solution.

なお、さらにこの溶液に」二組の従来既知の非特異凝集
反応阻止物質を混合してもよい。担体としては、自体既
知のものが使用され、具体的には、たとえばヒツジ、モ
ルモット、0型の人、ニワト−リl(どの赤血球をホル
マリン、グルタルアルデヒドi(どで固定したものなど
があけられ、これらのうちでも特に好ましいものはヒツ
ジ赤血球および0型の人赤面球である。このような担一
体は約20μ以下、特に5〜15μ程度のネ)!、状の
ものを使用するのが有利である。このような担体に抗体
又は抗原を(嵌作させる処理は自体公知の方法に準じて
行うことができる。
Furthermore, two sets of conventionally known non-specific agglutination reaction inhibiting substances may be further mixed into this solution. As carriers, those known per se are used, and specifically, for example, sheep, guinea pigs, type 0 humans, chickens (red blood cells fixed with formalin, glutaraldehyde, etc. Of these, particularly preferred are sheep red blood cells and type 0 human red blood cells.It is advantageous to use such carriers with a diameter of about 20μ or less, particularly about 5 to 15μ. The process of loading the antibody or antigen onto such a carrier can be carried out according to a method known per se.

また組繊成分とは、たとえば各組織を微細に粉砕ないし
分解したもの(たとえば、細胞組織の1゜51i以下の
紹微糾分解物など)などであり、かかるH(微細分解物
は、たとえば組織をブレンター処理後超音波処理するこ
とによって、あるいはブレンター処理後パパイン等の休
日分解酵素処理をすることによって得らtl、消化1り
が総窒素111に対し非蛋白性窒≠21@が20〜70
%のものを用いることが好ましい。超音波処理における
条件は1通常30”C以下、lO〜20KH110〜6
0分間でJ)す、超音波処理後粒子口径2μの膜を通過
したものを用いることが好ましい。
In addition, the composition component is, for example, a finely crushed or decomposed tissue (for example, a finely decomposed product of cell tissue of 1°51i or less), etc. tl obtained by treating with ultrasonic waves after treatment with a blender, or by treating with a holiday-degrading enzyme such as papain after treatment with a blender, the total nitrogen content is 111, while non-protein nitrogen≠21@20-70
% is preferably used. The conditions for ultrasonication are 1. Normally 30"C or less, lO~20KH110~6
It is preferable to use particles that have passed through a membrane with a diameter of 2 μm after being subjected to ultrasonic treatment for 0 minutes.

実施例 モルモットに精製1]13s抗原を免疫してHB s抗
血清を得た。この抗11fll を肖を硫安分画法とイ
オン交換クロマトグラフィー法とで処理し精製H13s
抗1体を得、この精製トIBs抗体をグルタルアルデヒ
ドにより固定されたヒツジ赤血球に牌作してHBs抗体
(嶋作ヒツジ赤血球を得た。
Example Guinea pigs were immunized with purified 1] 13s antigen to obtain HBs antiserum. This anti-11flll was purified by ammonium sulfate fractionation and ion exchange chromatography.
Anti-HBs antibody 1 was obtained, and this purified IBs antibody was plated onto sheep red blood cells fixed with glutaraldehyde to obtain an HBs antibody (Shimasaku sheep red blood cells).

他方、本発明からなる水性俗媒として01μリン酸緩歯
% (pH7,5)に正常動物血t〜およびヒト又はヒ
ツジの胎盤分解成分を終taN9が00・1・伎び0.
4012(w/v)になる様に加え、コントロールとし
て無添加のものを用意した。確認試験の結果非特異凝集
をおこすことが分っているクエン酸a;f加入血漿の2
(ψ体(表中1及び2)をJj P HA法に従いこの
5抽類の溶媒を用いてマイクロプレート上でそれぞれ2
倍数希釈を行い、この希断列へ上記で得たHEs抗体挿
作ヒツジ赤而赤血球合した。
On the other hand, as an aqueous medium of the present invention, 01μ phosphoric acid (pH 7.5) is used to remove decomposed components of normal animal blood and human or sheep placenta.
4012 (w/v), and a control without additives was prepared. 2 of plasma containing citric acid a;f, which was found to cause non-specific agglutination as a result of confirmation tests.
(The ψ-bodies (1 and 2 in the table) were separated into 2 volumes on a microplate using these 5 extracts of solvent according to the Jj PHA method.
A multiple dilution was performed, and the HEs antibody-inserted sheep erythrocytes obtained above were incubated with this diluted array.

別lζHEs抗原が腸性の検体(3)につき同様に処理
、試験した。なお混合液t74は邊体希釈故25μLH
’Bs抗体賄作ヒツジ赤血球25μeであり室温で2時
間後の凝集の仲さく凝集1!F )を4.8.2.1の
評価とし、非んト集を評価0として表現した時第1表の
成11?を得た。
A specimen (3) containing another lζHEs antigen was treated and tested in the same manner. The mixed solution t74 is 25μLH due to body dilution.
'Bs antibody bribed sheep red blood cells 25 μe and agglutination after 2 hours at room temperature agglutination 1! F) is evaluated as 4.8.2.1, and when the non-collection is expressed as 0, the result of Table 1 is 11? I got it.

尚胎盤′Ml &を成分としては胎フ:キのミンチを1
07Q甲の水にて洗f4tせしめた後、p −H7,0
のリンハルナトリウムf’8Dに懸l匍し、ブレシダー
によって分解し、さらにH1音波処理し1.2μの膜を
jlJ過した沖欣を用いた。
Placenta 'Ml & as ingredients: 1 minced fetus
After washing f4t with 07Q water, p -H7,0
Okishin was used, which had been suspended in Linhal sodium f'8D, decomposed with a breather, treated with H1 sonication, and passed through a 1.2μ membrane.

(以下余日) 表   1 表1に示した結果より、ヒト組糸;ν成分又は、ヒツジ
組紗成分を0.01〜0,4%(W/v)の必用に添加
することにより非特異度広は1:64〜1:128から
l:4〜1:16にまで抑えら才1ている。また陽性に
’件ではこれらのものを添加しても影響はないことが判
る。
(Remaining days below) Table 1 From the results shown in Table 1, non-specific The width has been reduced from 1:64 to 1:128 to l:4 to 1:16. In addition, in the case of positive results, it can be seen that there is no effect even if these substances are added.

以−トの如く本発明からj(る凝集試験用水性l6媒は
、奢るしく凝集反応の炒LWを上ガ1させるものであっ
て、すぐ第1た6)集試験を可n1コとするものである
As described above, the aqueous l6 medium for flocculation tests according to the present invention is one that elegantly improves the flocculation reaction LW, making it possible to perform the first and sixth tests immediately. It is something.

以下に本発明を実7Ji11例に、Lつで示す。The present invention will be illustrated below with reference to 11 actual 7Ji examples.

実施例1 ヒツジ赤血球をグルタルアルデヒドで固定17、公知の
方法で抗H1ls抗体を感作して411体を得た。
Example 1 Sheep red blood cells were fixed with glutaraldehyde17 and sensitized with anti-H1ls antibody by a known method to obtain 411 cells.

本担体を用いた絣集試鹸用水件俗媒として、OIM I
Jン酸紛伸Ihをp H7,8にヒト飴弥′組緘hν5
分01%(W/V)を加えて赤血球凝集反応試験用水性
か奴を得た。組緑成、分は、実験(9+lにおける。;
1.!1!製と旧1様にして調製したものである。
As a water conditioner for Kasuri test soap using this carrier, OIM I
J-acid powder Ih was added to pH 7,8 and human candy was added to the mixture hν5.
01% (W/V) was added to obtain an aqueous solution for hemagglutination test. Composition green component, minute is experimental (in 9+l.;
1. ! 1! It was prepared using the same method as the original one.

実R11,イν112 二ワI・り赤血球をゲルタルアルデヒドで固定し公知の
方法でHB s抗原を竹作した。
Fruit R11, Iv112 Niwa I red blood cells were fixed with geltaraldehyde and HBs antigen was produced using a known method.

本生体を用いたんF集試験用水性俗紡として、09%塩
化ナトリウムな4イタにヒッジハ′り内組1“1し成分
をそ第1ぞ第101%idQ屋に加えたものを得た。
Using this living body, we obtained aqueous fabric for testing in the F series by adding 101% idQ to 09% sodium chloride.

実/1iliイゲ113 実111−410及び2で<4)だ水性溶媒に史に保存
バ11としてNaNaを加えたものを得た。
Fruit/1ili Ige 113 Fruit 111-410 and 2<4) An aqueous solvent was obtained in which NaNa was added as a preservation bar 11.

特許出i+、:i人 株式会社ミドリ十字代 理 人 
弁理士 *−as、・:   −手続前if(’;’:
’ (1茫) 1ち1イfl15フイ140月1ゴ1」’I!1.f’
l庁長官      殿1 1: f’lの)(、Jミ 昭(、,57〕1 特許 に11・、5141893号
2 発明の名称  赤血球凝集試験用水性溶媒゛3 浦
11をする古 」1叶1との閂「系 特訂出に(人 f]1□11 氏 ii (f’+ l’l・)株式会社ミ トリ十字
fi、  111i1にまり増JJIIする発明の数1
、明細1第6頁、第20行σ〕「夛ト蛋白1’h J 
’k r可溶性」に訂正する0
Patent issued i+: i person Midori Juji Co., Ltd. agent person
Patent attorney *-as,・: -if before procedure(';':
' (1 茫) 1chi1iifl15hui140月1go1'''I! 1. f'
Director-General of the l Office 1 1: f'l) (, J Miaki (, 57) 1 Patent 11, No. 5141893 2 Title of the invention Aqueous solvent for red blood cell agglutination test The number of inventions made by JJII is increased by 111i1.
, Specification 1, page 6, line 20 σ] "Croup protein 1'h J
Correct to 'k r soluble'0

Claims (1)

【特許請求の範囲】 +l)  4;f東試試験用担体して動物白米の胎盤組
織lid、分又はパノ)肉組織成分をJIIO,01〜
0.4%(w/v)の濃度に含有することを特徴とする
赤面球凝果試験用水件俗媒。 (2)担体が抗体+5(i、作ヒツジ赤血球であり、組
恒Jコシ1分がヒト及びヒト以外の動物胎Nr組織、ヒ
ト以外の動ゼ、1の1f’)肉組憧である特、i′f 
#r ’5F−のQil’1trr+第(1)項記載の
水性f/i’yL
[Scope of Claims] +l) 4;f Placental tissue (lid, minute or pano) of animal polished rice as a carrier for Token test JIIO, 01~
A water medium for blush bulb condensation test, characterized in that it is contained at a concentration of 0.4% (w/v). (2) The carrier is antibody + 5 (i, cultivated sheep red blood cells, 1 min is human and non-human animal fetal Nr tissue, non-human animal fetus Nr tissue, , i'f
Qil'1trr of #r'5F-+aqueous f/i'yL described in item (1)
JP14189382A 1982-08-16 1982-08-16 Aqueous solvent for testing clotting of red blood corpuscles Pending JPS5931454A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14189382A JPS5931454A (en) 1982-08-16 1982-08-16 Aqueous solvent for testing clotting of red blood corpuscles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14189382A JPS5931454A (en) 1982-08-16 1982-08-16 Aqueous solvent for testing clotting of red blood corpuscles

Publications (1)

Publication Number Publication Date
JPS5931454A true JPS5931454A (en) 1984-02-20

Family

ID=15302612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14189382A Pending JPS5931454A (en) 1982-08-16 1982-08-16 Aqueous solvent for testing clotting of red blood corpuscles

Country Status (1)

Country Link
JP (1) JPS5931454A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01320145A (en) * 1988-06-22 1989-12-26 Nissan Shatai Co Ltd Honeycomb structural body and manufacture of honeycomb structural body
US4964936A (en) * 1988-10-11 1990-10-23 Imi-Tech Corporation Method of making foam-filled cellular structures

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01320145A (en) * 1988-06-22 1989-12-26 Nissan Shatai Co Ltd Honeycomb structural body and manufacture of honeycomb structural body
US4964936A (en) * 1988-10-11 1990-10-23 Imi-Tech Corporation Method of making foam-filled cellular structures

Similar Documents

Publication Publication Date Title
DE2203377C3 (en) Water-insoluble immunological diagnostic reagent intended for an agglutination test
Cohen et al. Identification of blood group antigens and minor cell populations by the fluorescent antibody method
EP0064274B1 (en) Method for assaying antigen-antibody reactions and reagent therefor
Hakomori Differential reactivities of fetal and adult human erythrocytes to antisera directed against glycolipids of human erythrocytes
EP0344287B1 (en) Conservative whole blood sample preparation technique
CN113156143B (en) Method and reagent for specific identification of irregular blood group antibodies
US3562384A (en) Immunological indicator and test system
US5318913A (en) Reagent for the determination by hemagglutination of antibodies to bacterial toxins, method of preparation and application thereof
Heyns et al. Platelet aggregation in chronic idiopathic thrombocytopenic purpura.
JPS5931454A (en) Aqueous solvent for testing clotting of red blood corpuscles
JPH01107154A (en) Processed red blood-corpuscle and its manufacturing method
US3426123A (en) Diagnostic test for infectious mononucleosis with aldehyde treated equine erythrocytes
Lincoln et al. Mixed agglutination as a method for the determination of A, B and H blood groups of hair
US4331649A (en) Immune complex assay
JPH01301165A (en) Immunoassay
JPS6022295B2 (en) Aqueous solvent for red blood cell agglutination test
US5143826A (en) Method for identifying feline blood type B
US4224306A (en) Preparation of an infectious mononucleosis antibody neutralizing antigen and product thereof
USRE28548E (en) Method and reagents for the diagnosis of viral diseases
Jacob et al. Percentage Expression of Lewis B, Rh-e, N, and ABO Antigens in descents of Bonny Kingdom, Rivers State, Nigeria
US4228148A (en) Heterophil antibody differentiation (HAD) test
JPH0377461B2 (en)
JPS638426B2 (en)
JPS60257363A (en) Measuring method of fdp
Esposito et al. In vitro potency results from a collaborative study of Rh0 (D) Immune Globulin Reference Preparation